Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents by James Leong Wai Yeen et al.
ORIGINAL RESEARCH ARTICLE
published: 04 December 2014
doi: 10.3389/fphar.2014.00269
Strategy for communicating benefit-risk decisions: a
comparison of regulatory agencies’ publicly available
documents
James Leong Wai Yeen1, Sam Salek2,3* and Stuart Walker3,4
1 Center of Regulatory Excellence, Duke-NUS Graduate Medical School, Singapore, Singapore
2 Department of Pharmacy, University of Hertfordshire, Hatfield, UK
3 Institute for Medicines Development, Cardiff
4 Centre for Innovation in Regulatory Science, London, UK
Edited by:
Dominique J. Dubois, Université
Libre de Bruxelles, Belgium
Reviewed by:
Domenico Criscuolo, Genovax, Italy
Dominique J. Dubois, Université
Libre de Bruxelles, Belgium
*Correspondence:
Sam Salek, Department of
Pharmacy, University of
Hertfordshire, College Lane,
Hatfield, Herts AL10 9AB, UK
e-mail: mssalek@gmail.com
The assessment report formats of four major regulatory reference agencies, US Food
and Drug Administration, European Medicines Agency, Health Canada, and Australia’s
Therapeutic Goods Administration were compared to a benefit-risk (BR) documentation
template developed by the Centre for Innovation in Regulatory Science and a four-member
Consortium on Benefit-Risk Assessment. A case study was also conducted using a US
FDA Medical Review, the European Public Assessment Report and Australia’s Public
Assessment Report for the same product. Compared with the BR Template, existing
regulatory report formats are inadequate regarding the listing of benefits and risks,
the assigning of relative importance and values, visualization and the utilization of a
detailed, systematic, standardized structure. The BR Template is based on the principles
of BR assessment common to major regulatory agencies. Given that there are minimal
differences among the existing regulatory report formats, it is timely to consider the
feasibility of a universal template.
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INTRODUCTION
The evolution of the requirements for assessing the benefits and
risks of medicinal products has resulted in changes in the regu-
latory review process. Beyond the separate assessment of benefits
and risks, the emphasis is now on the balance between the two,
having to justify the potential harms in view of the efficacy claims
(Breckenridge, 2010). This balance can be expressed in a trans-
parent manner using a structured framework that aids in the
communication of the differences in opinions between regulators
and the pharmaceutical industry. In a changing society where the
demand is for transparency of such decision-making processes,
there is now a major challenge to adequately communicate the
relevant information to stakeholders.
As expectations of stakeholders change with the rapid advance-
ment of science, regulatory agencies need to adapt to meet
these changing requirements. In the European Medicines Agency
(EMA) Roadmap to 2015, one of the strategic areas identified was
the reinforcement of the benefit-risk balance assessment model
through a set of priority activities (European Medicines Agency,
2011a). These included looking at appropriate quantitative tools,
improving the quality and consistency of the outcomes, and
reviewing the European Public Assessment Reports (EPARs) to
improve communication of benefit-risk decisions to stakehold-
ers and to increase the involvement of patients, academia and
healthcare professionals. Similarly, since 2009 the US Food and
Drug Administration (FDA) have begun initiatives to explore
systematic approaches to assess and communicate benefits and
risks. Their initiatives have included the development of a frame-
work to characterize and provide a structure for the benefit-risk
assessment already existing in their decision-making processes,
as well as communicating the reasoning behind the decision
to all stakeholders (US Food and Drug Administration, 2012),
which has led to the current FDA five-step benefit-risk frame-
work. These steps are related to the five key areas to be discussed
in the assessment of a medicine, namely the analysis of the con-
dition, the medical need for the product, clinical benefits, risks
and risk management. Mullin, commented that this structured
framework has the potential to improve the predictability and
consistency of decision-making as it is capable of clearly out-
lining both the available evidence and the uncertainties (Centre
for Innovation in Regulatory Science, 2011). This would enable
the US FDA to articulate the consideration and clinical judg-
ment taken for the benefit-risk decision and hence improve the
transparency of the decision-making process (US Food and drug
Administration, 2013). The US FDA has also published its own
user’s guide on communicating benefits and risks, which provides
the expectations and standards for communication (US Food and
drug Administration, 2011). Similarly, Australia’s Therapeutic
Goods Administration (TGA) will be focusing on increasing
transparency through their new initiatives and engaging stake-
holders with a new framework for communicating the benefits
vs. risks approach in their regulation of medicines (Therapeutic
Goods Administration, 2013). This increase in transparency is
to be achieved through information that is easily understood by
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patients and consumers and shared with healthcare profession-
als. TGA aims to provide accessible, clear and consistent relevant
information through various multimedia platforms.
The results from a recent study (Leong et al., 2013) showed
that both regulatory agencies and pharmaceutical companies
believe that a benefit-risk framework would enhance the qual-
ity (transparency and consistency) of communication and should
provide documentation for a structured discussion, acting as a
tool for communication among peers within an organization
and between the organization and other stakeholders (Centre for
Innovation in Regulatory Science, 2012). This eight-step univer-
sal benefit-risk framework encompasses the principles of exist-
ing frameworks by other major regulatory agencies such as the
US FDA (US Food and drug Administration, 2013) and EMA
(European Medicines Agency, 2010) (Table 1).
In collaboration with CIRS, TGA, the Singapore’s Health
Sciences Authority (HSA), Health Canada and SwissMedic estab-
lished a four-member Consortium on Benefit-Risk Assessment
(COBRA), which aimed to develop a systematic qualitative
approach for the benefit-risk assessment of medicines in order
to facilitate joint and shared reviews. A benefit-risk (BR) doc-
umentation template, or BR Template, was developed based on
the EMA reflection paper (European Medicines Agency, 2008)
and reviewed by the Consortium through both retrospective and
prospective studies employing its use, with plans for making the
template more reflective of actual practice. This BR Template was
designed to enhance effective documentation and communica-
tion of decisions and was used as the basis of a comparison in
this study. The summary portion of this template was extracted
to produce a “stand-alone” BR Summary Template, with the
objective that this simplified template would suffice to meet
the needs of jurisdictions with emerging pharmaceutical mar-
kets. This study aims to review the publicly available assessment
reports to see if they adequately fulfill the functions found in the
BR Template and BR Summary Template.
The objectives of this study were to:
• Compare the format of publicly available assessment reports
from US FDA, EMA, Health Canada and TGA with the BR
Template and BR Summary Template
• Evaluate whether these four regulatory agencies have an effec-
tive approach to communicating benefit-risk decisions to all
stakeholders
• Examine the utility of the BR Summary Template for commu-
nicating benefit-risk decisions by the US FDA, EMA and TGA
using a case study approach
METHODS
DEVELOPMENT OF THE BR TEMPLATE AND BR SUMMARY TEMPLATE
A benefit-risk documentation template, or BR Template, was
developed based on the EMA reflection paper (guidance doc-
ument, 2008). This document contained those elements con-
sidered essential to the assessment of benefits and risks of
medicines. These elements were then transformed into a template
that allowed systematic documentation and editing. This initial
developmental template was then reviewed against the universal
framework so that it could support its underlying principles. The Ta
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template comprises six sections namely: Section 1, Background
(decision context); Section 2, Overall Summaries (quality, non-
clinical, human pharmacology, clinical); Section 3, Identified
Benefits and Risks (list of all benefits, list of all risks); Section 4,
Benefit-Risk Study Findings (benefits observed in pivotal and non-
pivotal studies, overall summary of risks, adverse effects/events,
and uncertainties); Section 5, Benefit-Risk Summary Table
and Expert Judgment (benefits—weighting/relative importance
and valuing, risks—weighting/relative importance and valuing);
and Section 6, Benefit-Risk Conclusions. This initial template was
assessed by the Consortium who evaluated its use in a feasibility
study, which led to minor amendments of the template incorpo-
rating all the feedback from the Consortium. This BR Template
was then applied in a retrospective study followed by a prospec-
tive study for the review of a number of products, which resulted
in the final version of the Benefit Risk Template.
It was considered beneficial by the Consortium that the addi-
tion of a Summary section to the BR Template would enhance
its internal and external value for communication purposes to
stakeholders. Therefore, a Summary section was developed by
the expert reviewers who identified the key features from the
BR Template (benefit-risk conclusions, decision context, identi-
fied benefits and risks, benefit-risk: weighting/relative importance
and valuing and benefit-risk management). It was later recog-
nized that the BR Template was going to be more relevant to
the review process employed by the established agencies, but the
Summary Template, as a shorter version, would be ofmore benefit
to the maturing agencies. The Summary Template has subse-
quently been validated by several agencies that have carried out
retrospective reviews of a number of products.
COMPARISON OF THE PUBLICLY AVAILABLE DOCUMENTS FROM FOUR
REFERENCE AGENCIES
In order to establish the utility of the BR Template, reference agen-
cies were selected based on the criteria of a positive history, global
recognition and the public availability of assessment reports. For
the purpose of comparison in this study, the following report
formats of the four reference agencies were selected:
• US FDA—Medical Review and the Benefit-Risk Assessment
• EMA—European Public Assessment Report and the Executive
Summary
• Health Canada—Summary Basis of Decision
• TGA—Australian Public Assessment Report
Report formats were retrieved online for each agency and where
appropriate, a recent publicly available assessment report would
be used to review the contents of the format or support the under-
standing of the format. A comparison of the report formats from
the four reference agencies was conducted by reviewing the sec-
tion headings of the report against those of the BR Template and
BR Summary Template. Where there was a summary in the refer-
ence agency format, this would be directly compared with the BR
Summary Template and the findings are tabulated and presented.
Furthermore, to illustrate the use of the BR Summary
Template, a case study was conducted using a recent US
FDA Medical Review (European Medicines Agency, 2013a),
EPAR (Therapeutic Goods Administration, 2014) and AusPAR
(European Medicines Agency, 2011b) for the same product. Ziv-
aflibercept, indicated for the treatment of metastatic colorectal
cancer, was chosen as it was approved around the same time
by the agencies (03 August 3, 2012 for US FDA, February 1,
2013 for EMA and April 2, 2014 for TGA). Importantly, the US
FDA Medical Review was written according to the new five-step
benefit-risk framework that features the Benefit-Risk Assessment.
These two respective summaries were transferred into the BR
Summary Template and the omissions reviewed. This entire study
was designed to be exploratory and the outcomes were interpreted
to provide qualitative inferences relating to the aims. No statistical
analyses were planned or conducted.
RESULTS
The outcomes are presented in three parts:
• Part I—Formats of the four reference agencies’ publicly avail-
able reports
• Part II—Comparison of the four reference agencies’ report
formats with the BR Template and BR Summary Template
• Part III—Case study of US FDA, EMA and TGA sum-
mary reports on ziv-aflibercept (Zaltrap®; Regeneron
Pharmaceuticals, Inc./Sanofi-Aventis U.S. LLC, Bridgewater,
NJ, USA)
PART I—FORMATS OF REFERENCE AGENCIES’ PUBLICLY AVAILABLE
REPORTS
US FDA medical review
The US FDA Medical Review consists of nine sections (Table 2),
with the opening section presenting the recommendations and
benefit-risk assessment (based on the five-step benefit-risk frame-
work). The remaining sections present the details of the assess-
ment supporting the recommendations. It is known that the
publicly available reports from US FDA are a redacted subset of
the complete evaluation data. The original dataset would have
included discussions of queries and responses by the sponsor with
the US FDA.
The US FDA five-step benefit-risk framework appears to
closely reflect the format of its benefit-risk Assessment (Table 3),
and therefore was compared with the BR Summary Template.
Although the five-step benefit-risk framework may appear less
comprehensive than other existing frameworks, the US FDA is
currently reviewing a list of questions that should be included
under each of these steps, in an approach similar to the EMA
guidance for the assessment of benefits and risks.
EMA EPAR
The EPAR consists of an Executive Summary and four sections
(Table 4). The publicly available EPAR is extracted from the com-
plete assessment report which would have included responses and
justifications to EMA for queries raised.
Health Canada summary basis of decision
The Health Canada’s Summary Basis of Decision (SBD) consists
of eight sections (Table 5). This is a publicly available document
that presents the relevant information to support the decision
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Table 2 | Format of US FDA medical review.
Section Content
1 Recommendations/ Risk benefit assessment
2 Introduction and regulatory background
Product information
Tables of currently available treatment
for proposed indications
Availability of proposed active ingredient in US
Important safety issues with consideration to
related drugs
Summary of pre-submission regulatory activity
related to submission
Other relevant background information
3 Ethics and good clinical practices
Submission quality and integrity
Compliance with GCP
Financial disclosures
4 Significant efficacy/safety issues related
to other review disciplines
Chemistry manufacturing and controls
Clinical microbiology
Preclinical pharmacology/toxicology
Clinical pharmacology (mechanism of action,
pharmacodynamics, pharmacokinetics)
5 Sources of clinical data
Tables of studies/clinical trials
Review strategy Discussion of individual
studies/clinical trials
6 Review of efficacy
Efficacy summary
Indication (methods, demographics,
subject disposition)
Protocol violationsAnalysis of primary
endpoints
Analysis of secondary endpoints
Other endpoints
Subpopulations
Analysis of clinical information relevant to
dosing recommendations
Additional efficacy issues/analyses
7 Review of safety
Safety summary
Methods (studies, categorization, pooling of data)
Adequacy of safety assessment (overall exposure, dose response, special animal and/or in vitro testing, metabolic/clearance/interaction
workup, potential AE for similar drugs)
Major safety results (deaths, non-fatal SAE, dropouts/discontinuation, significant AE, specific primary safety concern
Supportive safety results (common AE, lab findings, vital signs, ECGs, special safety studies, immunogenicity)
Other safety explorations (dose dependency, time dependency, drug-demographic/drug-disease/drug-drug interactions
Additional safety evaluations (human carcinogenicity, human reproduction/pregnancy data, pediatric and effects on growth, overdose/abuse
potential/withdrawal/rebound
Additional submissions/safety issues
8 Post-market experience
Table 3 | US FDA Benefit-risk framework.
Decision Evidence and Conclusions
factor uncertainties and reasons
Analysis of condition
Current treatment options
Benefit
Risk
Risk management
Benefit-risk summary assessment
made by Health Canada for the product (Health Canada, 2012a).
Unlike the US FDA Medical Review and the EPAR, there is
no separate summary portion, as the SBD is meant for this
purpose.
TGA Australian public assessment report
The TGA Australian Public Assessment Report (AusPAR) con-
sists of six sections (Therapeutic Goods Administration, 2012)
(Table 6), the format being close to the EPAR but without the
Executive Summary. As with the formats of the other three
agencies, agency-specific information is that related to individ-
ual regulatory and submission information. It is known that
the AusPAR contains information extracted from the complete,
original assessment reports.
PART II—COMPARISON OF THE FOUR REFERENCE AGENCIES’ REPORT
FORMATS WITH THE BR TEMPLATE AND BR SUMMARY TEMPLATE
The formats of the reference agencies’ reports are generally sim-
ilar when compared with the BR Template (Walker et al., 2014).
They were all found to lack the features that list: (1) the identified
benefits and risks; (2) application of values and weights (relative
importance); and (3) visualization of the assessment outcomes
(Supplementary material). In addition, while it is acknowledged
that relevant discussions and considerations contributing to the
final benefit-risk decision maybe reported in the existing refer-
ence agencies’ reports, the BR Template allowed for this through
a structure of guided questions.
In comparison with the BR Summary Template, it was
found that only two reference agencies have defined summaries
within the report. The US FDA Medical Review has the
Recommendations/Benefit-Risk Assessment, which is a
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Table 4 | Format of EMA EPAR.
Executive Summary
1 Background information on the procedure Submission of the dossier Steps taken for the assessment of
the product
2 Scientific discussion and introduction
Quality aspects
Introduction
Active substance
Finished medicinal product
Discussion on chemical, pharmaceutical and biological aspects
Conclusions on the chemical, pharmaceutical and biological
aspects
Recommendations for future quality development
Clinical aspects
Introduction
Pharmacokinetics
Pharmacodynamics
Discussion on clinical
pharmacology
Conclusion on clinical
pharmacology
Clinical safety
Discussion on clinical safety
Conclusion on clinical safety
Pharmacovigilance
User consultation
Non-clinical aspects
Introduction
Pharmacology
Pharmacokinetics
Toxicology
Ecotoxicity/environmental risk assessment
Discussion on non-clinical aspects
Conclusion on non-clinical aspects
Clinical efficacy
Dose response studies
Main studies
Supportive studies
Discussion on clinical efficacy
Conclusion on clinical efficacy
3 Benefit-risk balance
4 Recommendations
discussion based on the benefit-risk framework employed by US
FDA. The Executive Summary of the EMA EPAR does not have
a structure and presents the information in a general discussion.
The entire Health Canada SBD and TGA AusPAR were compared
to the BR Summary Template, as it is the intent of both to func-
tion as summaries of the actual assessment reports. Details of the
comparison with the BR Summary Template are found in Annex
B in (Supplementary Material).
US FDA medical review
The approach of the US FDA Medical Review and the BR
Template was found to be similar, with the focus on the
contribution of clinical efficacy and safety to the overall benefit-
risk balance and a significant contribution of quality, non-clinical
and pharmacology concerns succinctly discussed.
Overall, it was observed that the US FDA Medical Review was
designed to present details of the evaluation processes including
those of the studies and considerations, while the BR Template
presents only the information that will directly contribute to
the decision on the benefit-risk balance. This can be seen in
the detailed structure of the US FDA Medical Review, compared
with the more concise BR Template. In terms of utility, the BR
Template and BR Summary Template appear to share the US
FDA Medical Review’s capability to present critical information
regarding the benefit-risk decision. The more explicit display
using the BR Template’s method of listing identified benefits and
risks, use of weighting, valuing and visualization may facilitate an
improved outcome through a more structured format on the dis-
cussion for benefit-risk balance and therefore enhance commu-
nication to stakeholders for whom this information is important.
Comparison with the BR Summary Template behaved exactly the
same as the BR Template exhibiting the same attributes.
EMA EPAR
In assessing the benefit-risk balance, the BR Template provided
a more structured format through the use of guiding questions,
while the EPAR was a general descriptive write-up. The deficien-
cies seen in the EPAR were found to be similar to those observed
for the US FDA Medical Review.
The Executive Summary of the EPAR was compared with
the BR Summary Template, which presents structured, concise
information leading to the benefit-risk decision, exceeding the
utility of the Executive Summary in the EPAR. Therefore, the BR
Summary Template may communicate the outcomes in a more
transparent manner than the Executive summary in the EPAR.
Health Canada SBD
In the assessment of efficacy and safety, it appears that the SBD
does not provide a detailed structure in presenting information
compared with the BR Template. Overall, both the SBD and BR
Template are comparable for the documentation of clinical effi-
cacy, safety and benefit-risk assessment. The SBD, however, did
not provide a list of benefits and risks that were considered and
subsequently excluded or included in the benefit-risk assessment.
Again, weighting (relative importance), valuing and visualization
were not included, which would improve transparency as well
as communicating the basis of decision. These deficiencies were
similarly observed when the SBD was compared with the BR
Summary Template.
TGA AusPAR
As observed in the other three publicly available documents, the
AusPAR was deficient in that it did not provide a list of benefits
and risks that were considered, nor did it include their relative
importance, their values, or any visualizations. As observed with
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Table 5 | Format of Health Canada summary basis of decision.
Section Content Purpose
PAAT Post-Authorization
Activities Table
List of post-authorization activities
for the approved product
1 What was approved? Information on approved
indication, intended population,
contraindications and product
presentations
2 Why was <product>
approved?
Discussion on basis of
benefit-risk balance
3 What steps led to the
approval of <product>?
Submission milestones
4 What follow-up
measures will the
company take?
Information on post-approval
commitment
5 What post-authorization
activity has taken place
for <product>?
Information provided as link to
earlier section on
Post-Authorization Activity Table
(PAAT)
6 What other information
is available about drugs?
Links to other webpages within
Health Canada website
7 What was the scientific
rationale for Health
Canada’s decision?
Details on:
a) Clinical Basis of Decision
i. Clinical pharmacology
ii. Clinical efficacy
iii. Clinical safety
iv. Safety topics of special
interest
b) Non-clinical Basis of Decision
c) Quality Basis of Decision
the other agencies, additional features of the BR Template may
help increase the effectiveness of discussion and communication.
It was observed that there was no defined summary for
the AusPAR, the section on overall conclusion and the benefit-
risk assessment appears to function similarly to the US FDA
Recommendations/Benefit-Risk assessment and EPAR’s executive
summary. The AusPAR appears to represent most of the func-
tional sections of the BR Summary Template, although it still has
the deficiencies detailed above.
PART III—CASE STUDY OF THE US FDA, EMA AND TGA SUMMARY
REPORTS ON ZIV-AFLIBERCEPT
Ziv-aflibercept was approved by both US FDA and EMA and
the publicly available Medical Review (US Food and Drug
Administration. Medical Review, 2012) and EPAR (European
Medicines Agency, 2013a) were retrieved from the internet. Both
of these documents provided similar information (Table 7), but
presented in a different manner. The Executive Summary was
written in a continuous descriptive prose but the US FDA Benefit-
Risk Assessment was presented under six headings. Overall, the
BR Summary Template is more structured in presenting the
information for the benefit-risk decision.
US FDA benefit-risk assessment
The BR Summary Template was completed with the informa-
tion (Annex C in Supplementary Material) from the Benefit-Risk
Table 6 | Format of TGA AusPAR.
Section Content
1 Introduction to product
submission
Submission details
Product background
Regulatory status
Product information
List of abbreviations
2 Quality findings
Drug substance
Drug product
Biopharmaceutics
Advisory committee considerations
Quality summary and conclusions
3 Non-clinical findings
Introduction
Pharmacology
Pharmacokinetics
Toxicology
Non-clinical summary and conclusions
4 Clinical findings
Introduction
Pharmacodynamics
Pharmacokinetics
Dosage selection for pivotal studies
Efficacy
Safety
Clinical summary and conclusions
5 Pharmacovigilance
findings
Risk management plan
OVERALL CONCLUSION AND RISK/BENEFIT ASSESSMENT
6 Background
Quality
Non-clinical
Clinical
Risk management plan
Risk-benefit analysis
Outcome
Assessment for ziv-aflibercept. The decision context of the BR
Summary Template could be sufficiently completed with infor-
mation from this report. Conclusions on quality, non-clinical,
and human pharmacology were absent from the Benefit-Risk
Assessment.
The benefits were included for the benefit-risk assessment
but no reasons were provided for their inclusion. There was
no information provided on those benefits that were reviewed
but subsequently excluded. Safety parameters included could be
inferred by the reasons provided in the Benefit-Risk Assessment
but the risks reviewed and subsequently excluded were not doc-
umented. Weighting (relative importance) and valuing were not
documented and there were no specific comments on the uncer-
tainties relating to the listed benefits and risks. The section of the
BR Summary Template (Section 7 of Annex B in Supplementary
Material) could be completed from this report although not pre-
sented in a structured manner. Overall, application of the BR
Summary Template to the US FDA Benefit-Risk Assessment pro-
vided a more structured and guided discussion of the decisions
leading to the eventual benefit-risk balance.
EPAR executive summary
The BR Summary Template was completed with the information
(Annex C in Supplementary Material) from the EPAR Executive
Summary. The Executive Summary has no structure and is pre-
sented in a single section. The quality, non-clinical, human phar-
macology conclusions of the BR Summary Template could not
be completed as they were absent from the Executive Summary
and this is a similar situation to that observed with the US
FDA Benefit-Risk Assessment. As there was no specific safety
summary, the clinical conclusion of the BR Summary Template
remained incomplete. The benefits included for benefit-risk
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Table 7 | Case study using Ziv-aflibercept—comparison of US FDA, EMA and TGA summaries with BR summary template.
BR Summary template US FDA EMA TGA
Content Risk benefit
assessment
EPAR—executive
summary
AusPAR—overall
conclusion
1.1 Background (Decision context)
1.1.1 Specify proposed therapeutic indication
√ √ √
1.1.2 Treatment modalities evaluated
√ √ √
1.1.3 Medical need
√ √ √
2.1 Overall summaries
2.1.1 Quality conclusions Not available Not available
√
2.1.2 Non-clinical conclusions Not available Not available
√
2.1.3 Human pharmacology conclusions Not available Not available
√
2.1.4 Clinical conclusions
√ √ √
3.1 Identified benefits and risks
3.1.1 Listing of all benefits, and justification for inclusion and exclusion Not available Not available Not available
3.1.2 Listing of all risks, and justification for inclusion and exclusion Not available Not available Not available
4.1 Clinical study summary
√ √ √
5.1 Risks: Overall summary Not available Not available
√
6.1 Weighting and valuing of benefits and risks Not available Not available Not available
7.1 Conclusion
7.1.1 For negative benefit-risk balance, discussion on the harm Not applicable Not applicable Not applicable
7.1.2 Discussion on evolution of the benefit-risk balance Not available
√ √
7.1.3 Discussion on outstanding issues and other significant information
(hearings, advisories, patients, consumers, stakeholder inputs)
Not available Not available
√
7.1.4 Discussion on pharmacovigilance plans and risk mitigation plans
√
Not available
√
7.1.5 Discussion on need for further studies
√ √ √
7.1.6 Any other information relevant to the benefit-risk decision
√
Not available
√
7.1.7 Conclusion on the benefit-risk balance for proposed indication
√ √ √
7.1.8 Recommendation indication
√ √ √
assessment are presented in the Executive Summary of the EPAR
but there were no reasons for their inclusion. In addition, there
were no indications for those benefits excluded or reasons for
their exclusion. A similar pattern was observed for the safety
parameters.
Sufficient information was provided in the Executive
Summary to complete the BR Summary Template clinical study
information and tables, but no weights, values or comments on
uncertainties were available. The above observations are expected
as relative importance is carried out implicitly but not explicitly
in many agencies. However, the safety exposure information was
written entirely as a paragraph and could not be uploaded as an
image into the BR Summary Template. The structured discussion
of the BR Summary Template was not adequately completed
using the Executive Summary.
TGA overall conclusion and risk/benefit assessment
The BR Summary Template was completed with informa-
tion from the Overall Conclusion (Annex C in Supplementary
Material). This last section of the main AusPAR (Therapeutic
Goods Administration, 2014) is organized into seven headings,
namely background, quality, non-clinical, clinical, risk manage-
ment plan, benefit-risk analysis and outcome. Compared with
BR Summary Template, it appears that it may have an advantage
over this summary by expressing the required information in a
succinct way.
DISCUSSION
The comparisons conducted in this study have shown that the for-
mats of the publicly available assessment reports from the four
reference agencies are similar and generally allow the information
generated through the course of the evaluation to be described.
The differences between these reports are largely related to their
format arrangement and headings provided for each section.
While there is no universal template for an assessment report,
there does not appear to be major differences as to how such
information should be presented. Thus, given the commonalities
with their presentation, only minor changes are required to their
current formats in order to achieve a potential universal standard
structure.
The publicly available assessment reports are the means for
documenting the relevant information made available to stake-
holders and to communicate the basis and justification for BR
decisions. The US FDA has made a recent attempt through
PDUFA V, to provide a Benefit-Risk Assessment, based on their
five-step framework, which details their considerations contribut-
ing to the regulatory decision and features an additional succinct
benefit-risk assessment summary. EMA has commissioned an
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external expert to improve its communication of benefits and
risks (European Medicines Agency, 2011b) and the EPAR fea-
tures an Executive summary to provide concise information.
Health Canada has completed its two phases of the initiative to
improve documentation and communication to the public, with
an emphasis on the discussion of the benefit-risk balance and the
basis of the decision (Health Canada, 2012b). Likewise, TGA has
commenced a project targeted at improving communication of
information to patients and physicians. Therefore, it is concluded
that these agencies recognize the need to effectively communicate
the basis of their decisions through a concise documentation tool.
The primary concern of most patients would be to know if a
product is effective and safe, while the physicians would want to
know the details to make a better informed decision when choos-
ing an optimal treatment for their patients. Therefore, clarity in
the presentation of such information is of paramount impor-
tance. For pharmaceutical companies, a documented transparent
decision-making process would enable them to understand the
basis of the regulatory decision, the rationale for the inclusion
or exclusion of benefits and risks, as well as the final benefit-
risk balance. This would, therefore, provide a suitable platform
to discuss any discrepancies in interpretation or differences in
opinions. In evaluating the product for pricing and reimburse-
ment, HTA agencies would also want to understand the rationale
for the approval of a product. A failure to achieve this under-
standing might affect a product’s accessibility for patients and
influence the healthcare delivery in terms of cost and clinical
management. Assessment reports of major regulatory agencies
are often accessed by smaller agencies in the emerging markets
to support their local decisions and thus these regulatory agen-
cies should also be considered as key stakeholders for the publicly
available assessment reports.
Certain jurisdictions may require publication of the assess-
ment reports as a move to increase the transparency of the
decision-making processes while others may require varying
amounts of information to be made public. As previously dis-
cussed, it is also not known if the current practices of providing
the publicly available assessment reports actually achieve the
transparency required or desired by the stakeholders as there
are no studies describing this type of feedback from pharma-
ceutical companies, physicians, patients or regulatory agencies.
In fact, the vast amount of unstructured information pro-
vided may possibly hamper understanding and thus communi-
cation. The use of summaries like the Executive Summary of
the EPAR, the Benefit-Risk Assessment of US FDA and Overall
Conclusion of the AusPAR aims to further improve communi-
cation. However, as seen in this case study of ziv-aflibercept, a
more structured and guided discussion, such as that provided
by the BR Summary Template, may further help to improve
both transparency and communication and prevent the omission
of information assessed by the reviewer and deemed impor-
tant to stakeholders. The comparison of the summaries showed
that there are elements missing which could facilitate effective
communication. As such, the elements from the BR Summary
Template found missing in the summaries of the reference agen-
cies may serve as a starting platform to enhance the effective-
ness in communicating benefit-risk decisions. Furthermore, the
provision of a list of identified benefits and risks and visual-
izations would aim to facilitate communication by reducing the
amount of text needed to convey these messages.
As a result of this study, future attempts to improve the quality
of communication should include the following:
• A listing of benefits and risks, with justification for their roles
in assessing the benefit-risk balance and the reasons for their
inclusion or exclusion
• Valuing the identified benefits and risks
• Weighting (relative importance) of the identified benefits and
risks
• Providing visualizations of the outcomes
• Utilizing guided discussions and structured questions such as
deliberations on uncertainties, consistency of outcomes across
studies and additional risks compared with a standard of
care to illustrate key discussion points leading to benefit-risk
decisions
Given that there are minimal differences among the existing
formats of the reference agencies, it is timely to consider the feasi-
bility of a universal template. The BR Template and BR Summary
Template were based on the EMA reflection paper (European
Medicines Agency, 2008) for the assessment of benefits and risks
and to allow documentation of these considerations in support
of the decision. Unlike the existing formats, the guided discus-
sion, structure, listings of identified benefits and risks, application
of values and weights and visualization of the BR Template serve
to improve effective communication. Familiarity with a standard
template and its presentation format will enhance the stakehold-
ers’ experience in seeking to understand the key messages. A
universal framework for the assessment of benefits and risks will
be required to bring focus to the agencies, which would then facil-
itate the implementation of a standard, universal documentation
tool.
An eight-step universal benefit-risk framework has been devel-
oped that incorporates the existing frameworks of major regula-
tory agencies and those used by pharmaceutical companies (US
Food and Drug Administration. Medical Review, 2012). Given
that the BR Template and BR Summary Template was developed
using the principles from this universal framework, there is now
the opportunity to explore their universal use. However, as the
basis for publicly available assessment reports, it would be pru-
dent to seekmore confirmative opinions from stakeholders on the
feasibility and utility of such an initiative through further studies.
In the course of this research, some areas for improve-
ment were identified for the BR Template and BR Summary
Template. These included expanding the discussion on pharma-
covigilance and RMP/REM, which would then align to the recent
requirements for periodic benefit-risk evaluation report (PBRER)
(European Medicines Agency, 2013b) and the emphasis on post-
market activities. As stakeholders are increasingly seeking the
acknowledgment of their opinions, there should also be dedicated
and defined areas for inputs from the various stakeholders, partic-
ularly patients. These improvements may enable the BR Template
to accommodate requirements in the post-marketing setting as
well as functioning as a tool for product life cycle management.
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If used as a universal template, it could trace and document the
evolution of the benefit-risk balance of a product and provide
meaningful comparisons using valid baselines. Ultimately, this
may translate to an increase in consistency, transparency and the
quality decision-making.
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